Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US market.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/second-anti-her2-tki-approved-nsclc-2025a1000wan?src=rss
Author :
Publish date : 2025-11-19 20:59:00
Copyright for syndicated content belongs to the linked Source.
